Skip to main navigation menu Skip to main content Skip to site footer
DOI:
https://doi.org/10.57187/4995

Original article

Vol. 156 No. 10 (2026)

Temporal trends in sedative medication use among hospitalised medical patients – a retrospective cohort study

Cite this as:
Swiss Med Wkly. 2026;156:4995
Published
23.10.2026

Summary

INTRODUCTION: Sedative psychopharmacological medications – including antipsychotics, antidepressants and hypnotics/anxiolytics – are frequently used to manage insomnia, agitation and psychiatric symptoms in hospitalised patients. However, their use carries substantial risks, particularly in older and multimorbid populations. This study examined temporal trends in sedative medication prescriptions and compared prescribing patterns from hospital admission to discharge on medical wards.

METHODS: This retrospective cohort study, using electronic health record data from a Swiss tertiary care hospital, studied 31,093 hospitalisations between 2019 and 2022. The primary outcome was quarterly prescribing trends of sedative medications (antipsychotics, antidepressants, and hypnotics, sedatives or anxiolytics) across the study years. Additionally, we explored differences between hospital admission and discharge and examined the proportion of prescriptions linked to a corresponding ICD-10 diagnosis.

RESULTS: From 2019 to 2022, discharge prescriptions increased for antipsychotics (8.4% in 2019 vs 11.7% in 2022, p for trend <0.001), decreased slightly for anxiolytics or sedatives (13.7% vs 12.6%, p = 0.06) and remained stable for antidepressants (13.8% vs 13.8%, p = 0.89). The proportion of patients without any sedative medication prescription decreased both over the study years (77.1% vs 74.8%, p <0.001) and during hospitalisation (77.6% on admission vs 75.7% at discharge, p <0.001). A considerable proportion of patients with a discharge prescription of any sedative medication did not have a corresponding diagnosis, including 50.1% for antipsychotics, 72.5% for antidepressants and 49.6% for anxiolytics or sedatives.

CONCLUSIONS: Sedative medication prescribing at hospital discharge increased over the study period, largely driven by rising antipsychotic use despite declining anxiolytic prescriptions. The frequent absence of a corresponding diagnosis raises concerns about potential overuse and continuation beyond appropriate clinical need. These findings highlight the need for improved prescribing practices, including systematic medication review and stronger use of non-pharmacological alternatives.

References

  1. 1. Chokhawala K, Stevens L. Antipsychotic Medications. Treasure Island (FL): StatPearls; 2025.
  2. 2. Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder. JAMA Network Open. 2019 Dec 27;2(12):e1918254. doi:10.1001/jamanetworkopen.2019.18254
  3. 3. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs. Journal of General Internal Medicine. 2007 Aug 10;22(9):1335-1350. doi:10.1007/s11606-007-0251-z
  4. 4. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews. 2009 Aug;13(4):265-274. doi:10.1016/j.smrv.2008.08.001
  5. 5. Riemann D, Perlis ML. The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Medicine Reviews. 2009 Jun;13(3):205-214. doi:10.1016/j.smrv.2008.06.001
  6. 6. Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlögl M. Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?—a critical appraisal of recent randomized controlled trials. Annals of Palliative Medicine. 2019 Sep;8(4):504-515. doi:10.21037/apm.2019.03.06
  7. 7. Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. American Journal of Psychiatry. 2016 May 1;173(5):543-546. doi:10.1176/appi.ajp.2015.173501
  8. 8. Ma'u E, Burton J, Fussell E. Antipsychotic and sedative medication use in long-term care facilities providing dementia care. N Z Med J. 2021;134(1537):56-65.
  9. 9. Hinkle CE, Davis JD, Arias I, Goldstein A, Daiello L, Margolis SA. Anticholinergic and sedative medication use in older patients with cognitive concerns. Journal of the American Geriatrics Society. 2024 Sep;72(9):2792-2799. doi:10.1111/jgs.18933
  10. 10. De Fazio P, Manfredi V, Gareri P, Bruni A, Ciambrone P, Cerminara G, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clinical Interventions in Aging. 2014 Aug:1363. doi:10.2147/CIA.S63942
  11. 11. Yunusa I, Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia. JAMA Network Open. 2019 Mar 22;2(3):e190828. doi:10.1001/jamanetworkopen.2019.0828
  12. 12. Corbett A, Burns A, Ballard C. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. 2014 Nov 3;349(nov03 1):g6420-g6420. doi:10.1136/bmj.g6420
  13. 13. Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. Advances in Therapy. 2022 May;39(5):1993-2008. doi:10.1007/s12325-022-02075-8
  14. 14. Medizin SGfrAI. Top-5-Liste - Stationäre Allgemeine Innere Medizin 2023 [Internet]. Available from: https://www.smartermedicine.ch/fileadmin/user_upload/Adaptionen/Congress/Informationen_Fachpersonen.pdf
  15. 15. Jahnsen JA, Widnes SF, Schjøtt J. Quetiapine, Misuse and Dependency: A Case-Series of Questions to a Norwegian Network of Drug Information Centers. Drug, Healthcare and Patient Safety. 2021 Jul;Volume 13:151-157. doi:10.2147/DHPS.S296515
  16. 16. Pek EA, Remfry A, Pendrith C, Fan‐Lun C, Bhatia RS, Soong C. High Prevalence of Inappropriate Benzodiazepine and Sedative Hypnotic Prescriptions among Hospitalized Older Adults. Journal of Hospital Medicine. 2017 May;12(5):310-316. doi:10.12788/jhm.2739
  17. 17. Soong C, Burry L, Cho HJ, Gathecha E, Kisuule F, Tannenbaum C, et al. An Implementation Guide to Promote Sleep and Reduce Sedative-Hypnotic Initiation for Noncritically Ill Inpatients. JAMA Internal Medicine. 2019 Jul 1;179(7):965. doi:10.1001/jamainternmed.2019.1196
  18. 18. Joglekar NN, Patel Y, Keller MS. Evaluation of Clinical Decision Support to Reduce Sedative-Hypnotic Prescribing in Older Adults. Applied Clinical Informatics. 2021 May;12(03):436-444. doi:10.1055/s-0041-1730030
  19. 19. Fixen DR, Farro SA, Shanbhag P, Parnes BL, Vejar MV. Multidisciplinary Approach to Deprescribing Sedative-Hypnotic Medications in Geriatric Primary Care. Journal of Primary Care & Community Health. 2022 Jan;13:21501319221103416. doi:10.1177/21501319221103416
  20. 20. van der Meer HG, Wouters H, Pont LG, Taxis K. Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: a randomised controlled trial. BMJ Open. 2018 Jul;8(7):e019042. doi:10.1136/bmjopen-2017-019042
  21. 21. Masnoon N, Lo S, Hilmer S. A stewardship program to facilitate anticholinergic and sedative medication deprescribing using the drug burden index in electronic medical records. British Journal of Clinical Pharmacology. 2023 Feb;89(2):687-698. doi:10.1111/bcp.15517
  22. 22. Hintze JP, Edinger JD. Hypnotic Discontinuation in Chronic Insomnia. Sleep Medicine Clinics. 2020 Jun;15(2):147-154. doi:10.1016/j.jsmc.2020.02.003
  23. 23. Al Rihani SB, Deodhar M, Darakjian LI, Dow P, Smith MK, Bikmetov R, et al. Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models. Drugs & Aging. 2021 Nov;38(11):977-994. doi:10.1007/s40266-021-00895-x
  24. 24. Farrar FC, White D, Darnell L. Pharmacologic Interventions for Pain Management. Critical Care Nursing Clinics of North America. 2017 Dec;29(4):427-447. doi:10.1016/j.cnc.2017.08.004
  25. 25. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off‐label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiology and Drug Safety. 2011 Feb;20(2):177-184. doi:10.1002/pds.2082
  26. 26. Schuler D, Roth S, Peter C. Psychopharmaka in der Schweiz. Mengen, Kosten, wer sie bezieht und wer sie verschreibt. 2022.
  27. 27. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008 Apr;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
  28. 28. Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie.
  29. 29. van Straten A, van der Zweerde T, Kleiboer A, Cuijpers P, Morin CM, Lancee J. Cognitive and behavioral therapies in the treatment of insomnia: A meta-analysis. Sleep Medicine Reviews. 2018 Apr;38:3-16. doi:10.1016/j.smrv.2017.02.001
  30. 30. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine. 2016 Jul 19;165(2):125-133. doi:10.7326/M15-2175
  31. 31. Magnusson DH, Albertsson TI, Jonsdottir F, Sigurdsson MI. The epidemiology of new persistent hypnotic/sedative use after surgical procedures: a retrospective cohort study. Anaesthesia. 2023 Aug;78(8):995-1004. doi:10.1111/anae.16041
  32. 32. Kennedy M, Koehl J, Gao J, Ciampa KA, Hayes BD, Camargo CA. Use of antipsychotic and sedative medications in older patients in the emergency department. Journal of the American Geriatrics Society. 2022 Mar;70(3):731-742. doi:10.1111/jgs.17590
  33. 33. van der Meer HG, Taxis K, Teichert M, Griens F, Pont LG, Wouters H. Anticholinergic and sedative medication use in older community‐dwelling people: A national population study in the Netherlands. Pharmacoepidemiology and Drug Safety. 2019 Mar;28(3):315-321. doi:10.1002/pds.4698
  34. 34. Zhang X, Zhou S, Li X, Zhou W, Zhou Y, Cui Y, et al. Anticholinergic and sedative medications exposure in older patients: a cross-sectional study. International Journal of Clinical Pharmacy. 2019 Oct;41(5):1152-1158. doi:10.1007/s11096-019-00885-5
  35. 35. Bushnell G, Ivanenko A, Horton DB, Lunsford-Avery JR, Posner J, Gerhard T, et al. Psychiatric comorbidities and prescribing tendencies of sleep medications and related medications in young people with insomnia: a United States commercial claims-based analysis. SLEEP. 2024 May 10;47(5):zsae057. doi:10.1093/sleep/zsae057
  36. 36. Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology. 2022 Feb;47(3):664-672. doi:10.1038/s41386-021-01163-7

Most read articles by the same author(s)

1 2 3 4 > >>